Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.76 |
| ▸ | CA12 | O43570 | 3/20 | 0.63 |
| ▸ | CA1 | P00915 | 3/20 | 0.63 |
| ▸ | CA2 | P00918 | 3/20 | 0.63 |
| ▸ | CA9 | Q16790 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | IDE | P14735 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.61 |
| ▸ | HLCS | P50747 | 1/20 | 0.58 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.58 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8407567 | 1.00 | TDP1 (0.76) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL18025829 | 1.00 | TDP1 (0.76) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL31621058 | 1.00 | TDP1 (0.76) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL19069314 | 1.00 | TDP1 (0.76) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL5841368 | 1.00 | TDP1 (0.76) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL24750115 | 1.00 | TDP1 (0.76) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL8333056 | 0.98 | TDP1 (0.73) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL24627775 | 0.97 | TDP1 (0.74) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL18779801 | 0.95 | TDP1 (0.78) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL19960973 | 0.94 | TDP1 (0.74) | TDP1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11517529-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| US-20200405638-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG INC (US) | 2020-12-31 | — | — | US | disclosed |
| US-20200261363-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG INC (US) | 2020-08-20 | — | — | US | disclosed |
| US-10568835-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10004686-B2 | Lipid construct for delivery of insulin to a mammal | SDG, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| EP-1883394-B1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG INC (US) | 2018-03-28 | — | — | EP | disclosed |
| US-9145453-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20100247625-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10568835-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | TDP1 4819/4885CA12 3452/4885CA1 2966/4885 |
| US-10004686-B2 | Lipid construct for delivery of insulin to a mammal | INSR, IAPP, GPR119 | TDP1 4882/4885CA12 2944/4885CA1 2697/4885 |
| US-11517529-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | TDP1 4819/4885CA12 3452/4885CA1 2966/4885 |
| US-20200405638-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | TDP1 4819/4885CA12 3452/4885CA1 2966/4885 |
| US-20200261363-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | INSR, IAPP, GPR119 | TDP1 4882/4885CA12 2944/4885CA1 2697/4885 |
| US-20100247625-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, LIPC, FABP6 | TDP1 4650/4885CA12 1226/4885CA1 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.